Giant papillary conjunctivitis (GPC) is a chronic inflammatory condition of the conjunctiva that causes papillae, or small bumps, to form on its surface. It is usually triggered by prolonged exposure to allergens from contact lenses, eye drops, or other foreign objects in the eye. Symptoms include redness, itching, burning, foreign body sensation, tearing, and crusting of the eyelids. GPC can seriously impact quality of life and even lead to loss of vision if left untreated.
The giant papillary conjunctivitis market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 1.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Growing demand for efficient treatment options for allergic and chronic eye diseases is driving the Giant Papillary Conjunctivitis Market. The increasing prevalence of dry eye disease, blepharitis, and contact lens complications has resulted in higher referral rates to ophthalmologists. Various pharmaceutical companies are engaged in developing novel drugs with fewer side effects.
Get More Insights On- Giant Papillary Conjunctivitis Market
Get This Report in Japanese Language: 巨大乳頭結膜炎市場
Get This Report in Korean Language: 거대 유두 결막염 시장
